Appointment of non-excecutive Independent Directors.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fredun Pharmaceuticals' Board, at its July 30, 2025 meeting, approved the unaudited financial results for Q1 FY26 (quarter ended June 30, 2025). On a standalone basis, total income from operations rose sharply to Rs. 11,985.50 lakhs from Rs. 7,881.08 lakhs in the same quarter last year, a growth of about 52%. Profit after tax climbed to Rs. 676.58 lakhs (vs Rs. 412.99 lakhs YoY), and EPS stood at Rs. 14.33 compared to Rs. 8.79 earlier. The statutory auditor, M/s. R.H. Nisar & Co., issued an unmodified limited review report on both standalone and consolidated results. Separately, the Board appointed Mr. Anshu Agarwal (a Chartered Accountant and US CPA currently working as an Audit Associate) and Ms. Sonal Desai (an experienced Company Secretary) as Additional Non-Executive Independent Directors for a five-year term, subject to shareholder approval. Both are confirmed independent of promoters and not debarred by SEBI or any authority.
This is a positive update for shareholders — strong YoY growth in both revenue (~52%) and profit (~64%) signals robust business momentum, while the addition of two qualified independent directors strengthens board governance. No negative governance flags were raised and the auditor's report was clean.